Incanthera PLC Notice of AGM and Posting of Annual Report (0588Z)
19 Maggio 2021 - 8:00AM
UK Regulatory
TIDMINC
RNS Number : 0588Z
Incanthera PLC
19 May 2021
19 May 2021
Incanthera plc
("Incanthera" or the "Company")
Notice of Annual General Meeting 2021 and Posting of Annual
Report and Accounts
Incanthera plc (AQSE: INC), the specialist oncology company
focused on innovative technologies in oncology and dermatology,
confirms that the Annual Report and Accounts for the year ended 31
March 2021, and the Notice of Annual General Meeting ("AGM") with
accompanying Form of Proxy has been posted to shareholders
today.
These documents are also available, in electronic form, for
download on the Company's website: www.incanthera.com
Incanthera's AGM will be held at 11:00 a.m. on Wednesday, 23
June 2021 at the offices of Gateley Plc, Ship Canal House, 98 King
Street, Manchester, M2 4WU.
Legislation and government guidance in the United Kingdom
relating to COVID-19 continues to place restrictions on public
gatherings, so shareholders are not encouraged to attend the
meeting in person. The Meeting will be held with the minimum
attendance necessary to form a quorum (which will be facilitated by
the Company) and will focus on the formal business of the meeting
only.
In order to ensure that shareholders are able to follow the
proceedings of the AGM, the Company will provide access online
through the Investor Meet Company platform. However, shareholders
will not be able to vote online during the Meeting and are
therefore urged to submit their votes via proxy as early as
possible, electronically or by post.
Shareholders are also invited to submit written questions for
the Board to consider. Questions can be pre submitted in advance of
the AGM via the Investor Meet Company Platform up to 9.00am on 22
June 2021, being the day before the AGM, or via the Investor Meet
Platform at any time during the AGM itself.
The Board will respond to key questions during the meeting and
will provide such answers on its website thereafter.
Shareholders who wish to attend the AGM online should register
for the event in advance via the following link:
https://www.investormeetcompany.com/incanthera-plc/register-investor
The Company will continue to monitor any changes to government
guidance over the coming weeks and will adapt our AGM arrangements
accordingly. The Company will communicate any updates to the AGM
arrangements via its website www.incanthera.com . Shareholders are
advised to check the Company's website for the most up to date
position.
The Board would like to take this opportunity to thank
Shareholders for their support and understanding of the necessary
precautions taken during this time, and to wish them well.
For further enquiries:
Incanthera plc
www.incanthera.com
Tim McCarthy, Chairman
tim.mccarthy@incanthera.com +44 (0) 7831 675747
Simon Ward, Chief Executive Officer
simon.ward@incanthera.com +44 (0) 7747 625506
Suzanne Brocks, Head of Communications
suzanne.brocks@incanthera.com +44 (0) 7776 234600
Aquis Exchange Corporate Adviser:
Cairn Financial Advisers LLP
Jo Turner/James Lewis/Mark Rogers +44 (0) 20 7213 0880
Broker:
Stanford Capital Partners Ltd
Patrick Claridge/John Howes/Bob Pountney +44 (0) 20 3815 8880
Notes to Editors
Incanthera is a specialist oncology company focused on
innovative technologies in oncology and dermatology . It seeks to
identify and develop innovative solutions to current clinical,
commercially relevant unmet needs, utilising new technology from
leading academic institutions.
The Company's current lead product and focus is Sol, a
potentially innovative topical product for the treatment of solar
keratosis and the prevention of skin cancers. This has achieved
proof of concept and the Company is now focussed upon delivering
Sol to a commercial partner.
The Company originated from the Institute of Cancer Therapeutics
("ICT") at the University of Bradford and has acquired and
developed a portfolio of specific cancer-targeting therapeutics
through a Pipeline Agreement with the ICT and other corporate
acquisitions.
Incanthera's strategy is to develop each candidate in the
portfolio from initial acquisition or discovery to securing its
future through commercially valuable partnerships at the earliest
opportunity in its development pathway.
For more information on the Company please visit:
www.incanthera.com
@incantheraplc
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXMZGMKRRKGMZM
(END) Dow Jones Newswires
May 19, 2021 02:00 ET (06:00 GMT)
Grafico Azioni Incanthera (AQSE:INC)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Incanthera (AQSE:INC)
Storico
Da Apr 2023 a Apr 2024